RVNC

Revance Therapeutics, Inc. [RVNC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RVNC Stock Summary

Top RVNC Correlated Resources

RVNC


Top 10 Correlated ETFs

RVNC


Top 10 Correlated Stocks

RVNC


In the News

04:27 08 Dec 2022 RVNC

Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey

FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc. A competing drug by the name of BOTOX was estimated to have generated more than $14.6 billion in sales in 2021.

10:26 08 Dec 2022 RVNC

Revance Therapeutics, Inc. (RVNC) Q3 2022 Earnings Call Transcript

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer & Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham & Company Operator Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

07:33 08 Dec 2022 RVNC

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:41 08 Dec 2022 RVNC

These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022

Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.

03:48 08 Dec 2022 RVNC

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

03:35 08 Dec 2022 RVNC

Revance Shares Jump 17% After FDA Approves Botox Rival

Revance Therapeutics says its new treatment, Daxxify, diminishes facial wrinkles for up to six months.

09:51 08 Dec 2022 RVNC

Why Is Revance Therapeutics (RVNC) Stock Soaring Today?

Revance Therapeutics (NASDAQ: RVNC ) stock is jumping 12% and trending on social media today. The company announced this morning that the Food and Drug Administration (FDA) had approved its alternative to Botox.

11:20 08 Dec 2022 RVNC

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2022 Results - Earnings Call Transcript

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jessica Serra - Head-Investor Relations and ESG Mark Foley - Chief Executive Officer Toby Schilke - Chief Financial Officer Conference Call Participants Operator Welcome to the Revance Therapeutics Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

07:33 08 Dec 2022 RVNC

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

04:05 08 Dec 2022 RVNC

Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

RVNC Financial details

Company Rating
Neutral
Market Cap
1.82B
Income
-273.57M
Revenue
108.59M
Book val./share
2.02
Cash/share
5.24
Dividend
-
Dividend %
-
Employees
495
Optionable
No
Shortable
Yes
Earnings
27 Feb 2023
P/E
-5.29
Forward P/E
-4.52
PEG
2.74
P/S
14.21
P/B
10.59
P/C
4.19
P/FCF
-4.67
Quick Ratio
5.22
Current Ratio
5.56
Debt / Equity
2.84
LT Debt / Equity
2.84
-
-
EPS (TTM)
-3.92
EPS next Y
-4.86
EPS next Q
-1.18
EPS this Y
-14.2%
EPS next Y
23.98%
EPS next 5Y
23.98%
EPS last 5Y
0.79%
Revenue last 5Y
212.27%
Revenue Q/Q
2.28%
EPS Q/Q
32.95%
-
-
-
-
SMA20
-
SMA50
-12%
SMA100
46.67%
Inst Own
96.47%
Inst Trans
14.59%
ROA
-38%
ROE
-462%
ROC
-0.41%
Gross Margin
69%
Oper. Margin
-239%
Profit Margin
-252%
Payout
-
Shs Outstand
82.27M
Shs Float
75M
-
-
-
-
Target Price
30.5
52W Range
11.27-30.95
52W High
-26.8%
52W Low
+99.64%
RSI
45
Rel Volume
0.31
Avg Volume
1.69M
Volume
524.13K
Perf Week
1.15%
Perf Month
-5.34%
Perf Quarter
61.59%
Perf Half Y
67%
-
-
-
-
Beta
0.544795
-
-
Volatility
0.34%, 0.75%
Prev Close
2.76%
Price
21.96
Change
0%

RVNC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.010.10.010.261.15
Net income per share
-4.01-3.94-3.67-4.86-4.17
Operating cash flow per share
-3.17-2.88-2.44-3.08-3.28
Free cash flow per share
-3.25-3.08-2.52-3.15-3.55
Cash per share
9.44.866.687.523.33
Book value per share
8.934.035.196.451.01
Tangible book value per share
8.934.035.192.69-1.98
Share holders equity per share
8.934.035.196.451.01
Interest debt per share
0.02003.424.9
Market cap
1.03B638.07M970.48M1.48B847.22M
Enterprise value
743.55M564.81M799.32M1.33B1.06B
P/E ratio
-8.51-4.48-6.09-5.23-3.01
Price to sales ratio
3.92K171.112.35K96.310.89
POCF ratio
-10.77-6.12-9.14-8.27-3.82
PFCF ratio
-10.48-5.73-8.87-8.08-3.54
P/B Ratio
3.824.384.33.9412.37
PTB ratio
3.824.384.33.9412.37
EV to sales
2.84K151.461.94K86.4813.64
Enterprise value over EBITDA
-6.27-4.1-5.11-5.11-4.16
EV to operating cash flow
-7.8-5.42-7.53-7.42-4.79
EV to free cash flow
-7.59-5.07-7.31-7.25-4.43
Earnings yield
-0.12-0.22-0.16-0.19-0.33
Free cash flow yield
-0.1-0.17-0.11-0.12-0.28
Debt to equity
0000.484.67
Debt to assets
0.090.360.340.480.87
Net debt to EBITDA
2.380.531.090.58-0.84
Current ratio
13.656.57.247.383.66
Interest coverage
-263.51-3.24K0-18.03-43.79
Income quality
0.790.730.670.630.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
142.7414.44150.159.770.36
Research and developement to revenue
306.7224.81249.068.211.49
Intangibles to total assets
0000.30.38
Capex to operating cash flow
0.030.070.030.020.08
Capex to revenue
-10.02-1.9-7.84-0.28-0.23
Capex to depreciation
-1.79-4.11-1.11-0.41-0.91
Stock based compensation to revenue
50.54.3643.392.380.56
Graham number
28.3718.920.6926.579.75
ROIC
-0.44-0.73-0.55-0.41-0.59
Return on tangible assets
-0.41-0.63-0.47-0.56-0.86
Graham Net
8.513.194.031.64-3.41
Working capital
264.31M175.95M255.62M389.04M178.83M
Tangible asset value
000155.98M-133.83M
Net current asset value
258.36M127.2M181.81M104.07M-216.58M
Invested capital
0000.494.74
Average receivables
938.5K14.41M01.83M2.59M
Average payables
9.73M10.55M10.33M12.66M11.63M
Average inventory
0005.88M8.02M
Days sales outstanding
66.872.64K043.5615.71
Days payables outstanding
000968.72165.32
Days of inventory on hand
000449.73158.32
Receivables turnover
5.460.1408.3823.24
Payables turnover
0000.382.21
Inventory turnover
0000.812.31
ROE
-0.45-0.98-0.71-0.75-4.11
Capex per share
-0.09-0.2-0.07-0.07-0.27

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.290.380.370.40.4
Net income per share
-1.1-0.93-0.94-0.88-1.17
Operating cash flow per share
-0.78-0.66-0.9-0.63-2.26
Free cash flow per share
-0.86-0.72-0.98-0.71-2.29
Cash per share
4.043.313.843.345.24
Book value per share
1.771.010.37-0.042.02
Tangible book value per share
-1.27-1.97-2.53-2.81-0.61
Share holders equity per share
1.771.010.37-0.042.02
Interest debt per share
4.834.797.246.36.02
Market cap
1.89B1.11B1.33B968.25M1.95B
Enterprise value
2.09B1.32B1.63B1.34B2.27B
P/E ratio
-6.35-4.4-5.18-3.94-5.75
Price to sales ratio
95.6442.7952.7534.1367.19
POCF ratio
-35.52-24.89-21.75-21.89-11.93
PFCF ratio
-32.35-22.67-19.98-19.51-11.8
P/B Ratio
15.7216.2252.17-368.0213.38
PTB ratio
15.7216.2252.17-368.0213.38
EV to sales
105.6951.0364.3947.1178.34
Enterprise value over EBITDA
-30.85-23.6-28.52-26.23-29.1
EV to operating cash flow
-39.25-29.68-26.55-30.22-13.91
EV to free cash flow
-35.75-27.04-24.39-26.93-13.75
Earnings yield
-0.04-0.06-0.05-0.06-0.04
Free cash flow yield
-0.03-0.04-0.05-0.05-0.08
Debt to equity
2.674.6718.35-157.732.84
Debt to assets
0.790.870.9610.8
Net debt to EBITDA
-2.93-3.81-5.16-7.23-4.14
Current ratio
4.463.664.023.385.56
Interest coverage
-46.29-39.16-32.22-14.93-11.2
Income quality
0.710.710.950.721.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.62-4.671.741.650
Research and developement to revenue
1.521.141.220.880.9
Intangibles to total assets
0.350.380.310.350.27
Capex to operating cash flow
0.10.10.090.120.01
Capex to revenue
-0.26-0.17-0.21-0.19-0.07
Capex to depreciation
-1.01-0.8-1.01-0.821.85
Stock based compensation to revenue
0.530.420.570.33-0.46
Graham number
6.624.582.810.867.3
ROIC
-0.14-0.13-0.11-0.12-0.12
Return on tangible assets
-0.2-0.19-0.15-0.17-0.16
Graham Net
-2.68-3.38-5.02-4.56-2.35
Working capital
228.01M178.83M214.26M183.72M340.86M
Tangible asset value
-86.29M-133.83M-172.6M-196.62M-44.12M
Net current asset value
-167.78M-216.58M-328.68M-303.57M-150.28M
Invested capital
2.714.7419.28-166.362.94
Average receivables
3.62M4.47M5.03M5.59M8.66M
Average payables
10.66M11.94M11.65M13.27M7.01M
Average inventory
11.9M11.88M12.13M13.6M15.39M
Days sales outstanding
7.5611.6115.9317.7336.39
Days payables outstanding
122.91121.08114.25125.437.71
Days of inventory on hand
155.84115.96121.52128.53178.09
Receivables turnover
11.917.755.655.072.47
Payables turnover
0.730.740.790.7211.67
Inventory turnover
0.580.780.740.70.51
ROE
-0.62-0.92-2.5223.35-0.58
Capex per share
-0.08-0.06-0.08-0.08-0.03

RVNC Frequently Asked Questions

What is Revance Therapeutics, Inc. stock symbol ?

Revance Therapeutics, Inc. is a US stock , located in Newark california of California and trading under the symbol RVNC

Is Revance Therapeutics, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $30.5. The lowest prediction is $24 and the highest is $37

What is RVNC stock prediction ?

With a median analyst target price of $37, 1 stock analysts have made 1 forecasts in last 90 days. $37 is the lowest and $37 is the greatest projection.

What is Revance Therapeutics, Inc. stock quote today ?

Revance Therapeutics, Inc. stock price is $21.96 today.

Is Revance Therapeutics, Inc. stock public?

Yes, Revance Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap